Trial Profile
Phase II trial of MK 8931 in patients with Alzheimer's disease.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2011
Price :
$35
*
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Merck & Co
- 16 Nov 2011 New trial record